Secondary End Points and Other Analyses
Bleeding, bleeding, death
BLEEDING, EVENTS, BLEEDING
The incidence of ISTH major bleeding events was similar among groups. No fatal bleeding events were observed. The relative risk of death from any cause and cardiac-related rehospitalization was similarly low in both rivaroxaban groups and the enoxaparin group (Landmark survival analysis of early and late events was also performed with 2 landmark time points (in-hospital and 30 days after randomization). Bleeding events or MACEs during hospitalization were rare and numerically lower in both low-dose oral rivaroxaban groups than in the enoxaparin group (